The presence of CTLA4+ Tregs in tumors and CTLA4– Tregs in adjacent tissues is in line with observations that anti‐CTLA4 therapies may target FOXP3+ Tregs to induce tumor rejection in melanoma.44 This evidence concerns the gene CTLA4 and neoplasm.